Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,986 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06364371Recruiting
Predicting rectal cancer treatment response using multi-omics
This trial is testing a new way to predict how well your rectal cancer will respond to treatments given before surgery. It uses advanced tests (like looking at genes and other markers) to tailor your care.
Guangzhou, GuangdongAges 18–80 - NCT06468358RecruitingPhase 1/Phase 2
LB1410 and LB4330 for advanced solid tumors
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06466265RecruitingPhase 1
Testing DNP002 for advanced solid tumors that have not responded to standard treatments
This trial tests a new drug called DNP002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if DNP002 is safe and can help shrink tumors or slow their growth.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05890287Recruiting
Chidamide plus hormone therapy after chemotherapy for breast cancer
This trial studies chidamide added to standard hormone (endocrine) therapy to help prevent breast cancer from coming back after initial chemotherapy. It may help by keeping cancer under control for longer in people with HR-positive, HER2-negative breast cancer who respond to first-line treatment.
TianjinAges 18–75 - NCT07441369Enrolling by invitationPhase 2
Abemaciclib with chemotherapy for advanced colorectal liver metastases
This trial tests combining the targeted drug abemaciclib with standard chemotherapy (FOLFOX or FOLFIRI) for people whose colorectal cancer has spread to the liver and cannot be removed surgically. It may be an option if you've already tried two or three prior treatments without success.
ShanghaiAges 18–75 - NCT05837039Recruiting
Comparing caregiver and nurse views of discomfort in advanced cancer
This study compares how healthcare providers and family caregivers judge discomfort in people with advanced cancer who are very hard to rouse and may be actively dying. It aims to understand whether caregiver and staff perceptions match, which could improve comfort care for patients near the end of life.
Houston, TexasAges 18 years+ - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT06703177RecruitingPhase 1/Phase 2
Study of SHR-1826 combo for advanced solid tumors
This trial tests a new drug, SHR-1826, combined with other cancer treatments for people with advanced solid tumors that have not responded to prior therapy. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT07283367RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
GuangzhouAges 18 years+ - NCT06410092RecruitingPhase 1
Safety study of FTL001 for advanced solid tumors
This trial tests a new drug called FTL001 for people with advanced solid tumors that have not improved with standard therapy. The goal is to see if it is safe and how well it works.
Beijing, Beijing MunicipalityAges 18–75 - NCT05620706Recruiting
GPC-3 CAR-T for advanced liver cancer
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
Shenzhen, GuangdongAges 40–70 - NCT06940349RecruitingPhase 1/Phase 2
Palbociclib and sunitinib for advanced solid tumors
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
Petah TikvaAges 18 years+ - NCT06132828RecruitingPhase 1
Testing DR30206 for advanced or metastatic solid tumors
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07262164RecruitingPhase 1
Testing VG2062 for advanced solid tumors
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
HebeiAges 18–75 - NCT07249112Recruiting
Genomic study of metabolic fatty liver disease
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
Milan, MilanoAges 18–90 - NCT06725381RecruitingPhase 1
Testing SKB571 for advanced solid tumors
This study tests an experimental drug called SKB571 for people with advanced solid tumors that have not responded to or stopped responding to standard treatments. The goal is to see if SKB571 is safe and to find the right dose.
Guangzhou, GuangdongAges 18–75 - NCT05536128RecruitingPhase 2
Fulvestrant plus DNA damage drugs after CDK4/6 treatment failure
This Phase 2 trial studies whether combining fulvestrant with medicines that block DNA repair can help treat HR+/HER2- metastatic or inoperable breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor. It also aims to check the safety of this combination and see if it can control the cancer for longer.
SeoulAges 19 years+ - NCT07317193Recruiting
Genetic causes of adult bile duct disease
This study looks for new genes that might cause abnormal liver test results or specific bile duct diseases in adults, when standard testing hasn't found a clear cause. It also uses healthy blood donors as a comparison group.
Milan, MilanoAges 18–65 - NCT05667194RecruitingPhase 1
Early study of KH617 for advanced brain and solid tumors
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06911489RecruitingPhase 1
Safety trial of a new targeted therapy for advanced solid tumors
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
ShanghaiAges 18–80 - NCT07680257RecruitingEarly Phase 1
CLDN18.2 CAR T cells for advanced solid tumors
This trial tests a new treatment called CLDN18.2 CAR T cells in people with advanced solid tumors that have a specific marker (CLDN18.2). It aims to see if it is safe and works against cancers that have not responded to standard treatments.
Hefei, AnhuiAges 18–75 - NCT05856383Recruiting
HER2-positive metastatic breast cancer drug combination study
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
Hangzhou, ZhejiangAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,986 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.